Global Sarcoma Drug Market 2024-2031

Global Sarcoma Drug Market 2024-2031

Sarcoma Drug Market Size, Share & Trends Analysis Report by Treatment Type (Chemotherapy, Targeted Therapy, Immuno Therapy, and Others), by Disease Indication (Soft Tissue Sarcoma (STS), Bone Sarcoma, Gastrointestinal Stromal Tumors (GIST), and Kaposi Sarcoma) and by Distribution Channel (Hospital Pharmacy, Retail pharmacy, and Online Pharmacy) Forecast Period (2024-2031)

Sarcoma drug market is anticipated to grow at a CAGR of 8.3% during the forecast period (2024-2031). Sarcomas are rare cancers that develop in the bones and soft tissues, including fat, muscles, blood vessels, nerves, deep skin tissues, and fibrous tissues. According to the National Cancer Institute, about 12,000 cases of soft tissue sarcomas and 3,000 cases of bone sarcomas are diagnosed annually in the US. The high incidence and prevalence of sarcomas has driven the demand for its treatment options thereby driving the global sarcoma drugs market. However, the high cost of these drugs may restrain the market growth.

Market Dynamics

Increasing healthcare expenditure

Healthcare spending, especially in North America, is bolstering the market owing to improved infrastructure and increased awareness of cancer treatments. According to the American Medical Association, in April 2024, health spending in the US rose by 4.1% to reach $4.4 trillion, equivalent to $13,493 per capita. This growth rate is consistent with the rates observed in 2019 before the pandemic. Although government spending to address the pandemic initially caused significant increases in National Health Expenditures (NHE), these expenses declined in 2021, while the utilization of medical goods and services rebounded. By 2022, health spending patterns had largely returned to the pre-pandemic levels.

Increased funding for sarcoma treatment research

The market for sarcoma research and clinical trials is being bolstered by increased funding from both government and private organizations. For instance, in March 2024, Lamassu Bio received a $2.05 million grant from the US National Institutes of Health (NIH) and National Cancer Institute (NCI) for the development of SA53, a new therapeutic for p53 wild-type sarcomas. The funding will advance the progression of the new cancer treatment into clinical trials. Lamassu Bio will carry out the trial in partnership with the Cleveland Clinic Taussig Cancer Center and the Cleveland Clinic Children’s Pediatric Hematology and Oncology Department. It will establish a safe dosage of SA53 for future trials.

Market Segmentation

Based on treatment type, the market is segmented into chemotherapy, targeted therapy, immunotherapy, and others.

Based on disease indication, the market is segmented into soft tissue sarcoma (STS), bone sarcoma, gastrointestinal stromal tumors (GIST), and Kaposi sarcoma.

Based on the distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy.

Gastrointestinal Stromal Tumors (GIST) Sub-segment to Hold a Considerable Market Share

The increasing number of GIST cases and improved diagnostic techniques are leading to higher detection rates and increased demand for effective treatments. According to the US Food and Drug Administration, in May 2020, the FDA approved ripretinib for adult patients with advanced gastrointestinal stromal tumors who have previously received treatment with kinase inhibitors. The drug was evaluated in an international trial, INVICTUS, which included 129 patients who received ripretinib or a placebo until disease progression or unacceptable toxicity. The major efficacy outcome measure was progression-free survival.

Regional Outlook

The sarcoma drug market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Holds Major Market Share

The increase in sarcoma cases necessitates improved diagnostic techniques and increased awareness for early detection and intervention. According to the American Society of Clinical Oncology (ASCO), in November 2023, it is projected approximately 13,400 new cases of soft-tissue sarcoma in the US, with 7,400 affecting men and boys and 6,000 affecting women and girls. Additionally, it is estimated 5,140 fatalities from this disease, with 2,720 occurring among men and boys and 2,420 among women and girls. The high investment by regional players in the development of sarcoma drugs is further aiding the regional market growth.

Market Players Outlook

The major companies serving the sarcoma drug market include Bayer AG, Eli Lilly and Co., Novartis AG, Merck & Co., Inc., and Pfizer Inc. among others. The market players are increasingly focusing on business expansion and product development by applying strategies such as collaborations, mergers and acquisitions to stay competitive in the market.